-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2795 Potent in Vitro and In Vivo Efficacy of BYON4413, a Duba-Based Antibody-Drug Conjugate Targeting CD123 in Acute Myeloid Leukemia

Program: Oral and Poster Abstracts
Session: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster II
Hematology Disease Topics & Pathways:
Research, Translational Research, Non-Biological therapies, Chemotherapy, Therapies
Sunday, December 10, 2023, 6:00 PM-8:00 PM

Miranda van der Lee1*, Tanja van Achtenberg1*, Annet Brouwers-Vos2*, Monique van der Vleuten1*, Wendy Kappers1*, Gijs Verheijden1*, Gerwin A. Huls, Prof.3, Glenn van Wigcheren1*, Ruud Ubink1*, Aloys Sesink1*, Alyson MacInnes1*, Jan Jacob Schuringa, PhD4 and Wim Dokter1*

1Byondis BV, Nijmegen, Netherlands
2University Medical Center Groningen, University of Groningen, Groningen, Netherlands
3University Medical Center Groningen, Groningen, Netherlands
4Department of Experimental Hematology, University Medical Center - Groningen, Groningen, Netherlands

Acute myeloid leukemia (AML) and myelodysplasia (MDS) result from a differentiation impairment driving an accumulation of immature myeloid cells in the bone marrow and peripheral blood. A widely reported feature of these neoplastic myeloid cells is an increased cell surface expression of CD123, the IL3 receptor α subunit. This observation has established CD123 as an attractive target for precision therapy. Here, we describe BYON4413, a novel antibody-drug conjugate (ADC) that binds with high affinity to CD123. BYON4413 comprises a humanized IgG1 antibody directed at CD123 that is site-specifically conjugated to Byondis’ proprietary duocarmazine linker-drug (LD) technology, ByonZine® and ByonShieLD®. This LD, when cleaved upon internalization and lysosomal routing, releases a potent duocarmycin payload that alkylates DNA, generating damage that results in replication stress and cell death. In vitro studies with AML cell lines demonstrate that BYON4413 is highly effective in eradicating CD123-positive cells while having little impact on CD123-negative cells. Similar results are observed when we test BYON4413 on AML patient-derived BMMCs/PBMCs in ex vivo assays (n=50), indicating that the specificity of BYON4413 cytotoxicity is largely limited to CD123-positive cells. Ex vivo experiments also reveal a stronger potency of BYON4413 in AML patient-derived blasts compared to healthy CD34+ hematopoietic stem/progenitor cells. In vivo PK/PD studies demonstrate that BYON4413 is remarkably efficient at reducing the tumor burden in multiple AML patient- and cell line-derived xenograft models. Studies in non-human primates suggest that BYON4413 has a favorable toxicity profile and a high maximum tolerable dose, features that should enable combination strategies with other oncolytics. In sum, BYON4413 shows great potential to be an effective targeted therapy against AML, MDS, and other CD123+ hematological malignancies such as blastic plasmacytoid dendritic cell neoplasm (BPDCN). Readied with these promising pre-clinical results, we have designed a first-in-human dose-escalation and expansion trial enrolling AML and high-risk MDS patients scheduled to begin in Q12024.

Disclosures: van der Lee: Byondis BV: Current Employment. van Achtenberg: Byondis BV: Current Employment. Brouwers-Vos: Byondis BV: Research Funding. van der Vleuten: Byondis BV: Current Employment. Kappers: Byondis BV: Current Employment. Verheijden: Byondis BV: Current Employment. van Wigcheren: Byondis BV: Current Employment. Ubink: Byondis BV: Current Employment. Sesink: Byondis BV: Current Employment. MacInnes: Byondis BV: Current Employment. Schuringa: Byondis BV: Research Funding. Dokter: Byondis BV: Current Employment.

*signifies non-member of ASH